author-photo

Wolf-Henning Boehncke

Goethe University Frankfurt
Geneva College
University of Geneva

339

Papers

7743

Citations

Citation Trend

Filter By

Papers (248) Sort By

Journal Conference Others

27847 Guselkumab (GUS) efficACy in TNF-inhibitor-experienced and TNF-inhibitor-naïve patients with active psoriatic arthritis (PsA): Results of a phase 3, randomized, controlled study

2021 Journal of The American Academy of Dermatology
Show All
- Source
- Cite
- Save
Citations (0)
German S3-Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – Part 2: Treatment monitoring and specific clinical or comorbid situations

2021 Journal Der Deutschen Dermatologischen Gesellschaft
Show All
- Source
- Cite
- Save
Citations (0)
LOOP, a cross-sectional, observational study investigating the clinical specialty setting as a determinant of disease management in psoriatic arthritis: Subgroup analysis results from Japan.

2021 PLOS ONE
Show All
- Source
- Cite
- Save
Citations (0)
Deutsche S3-Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm - Teil 2: Therapiemonitoring, besondere klinische Situationen und Komorbidität.

2021 Journal Der Deutschen Dermatologischen Gesellschaft
Show All
- Source
- Cite
- Save
Citations (0)
Voneinander lernen, miteinander behandeln

2021 Hautarzt
Show All
- Source
- Cite
- Save
Citations (0)
27529 Safety of guselkumab in patients with psoriatic arthritis through 1 year: Pooled findings from DISCOVER-1 and DISCOVER-2 phase 3 trials

2021 Journal of The American Academy of Dermatology
Show All
- Source
- Cite
- Save
Citations (0)
113 Psoriatic inflammation modulates mechanotransduction and cell adhesion in human epidermis

2021 Journal of Investigative Dermatology
Show All
- Source
- Cite
- Save
Citations (0)
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.

2021 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (18)
Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced.

2021 RMD Open
Show All
- Source
- Cite
- Save
Citations (4)
IL-25 (IL-17E) in epithelial immunology and pathophysiology.

2021 The Journal of Allergy and Clinical Immunology
Show All
- Source
- Cite
- Save
Citations (7)